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Tumour necrosis factor-α, interferon-γ and interleukin-4 are critical cytokines in regulating the immune responses against
infections and tumours. In this study, we investigated the eﬀects of three cytokines on CD40 expression in Myb-transformed
hematological cells and their regulatory roles in promoting these cells into dendritic cells. We observed that both interleukin-4
and interferon-γ increased CD40 expression in these hematological cells in a dose-dependent manner, although the concentration
required for interleukin-4 was signiﬁcantly higher than that for interferon-γ. We found that tumour necrosis factor-α promoted
CD40expressioninducedbyinterferon-γ,butnotbyinterleukin-4.Ourdatashowedthattumournecrosisfactor-αplusinterferon-
γ-treated Myb-transformed hematological cells had the greatest ability to take up and process the model antigen DQ-Ovalbumin.
Tumour necrosis factor-α also increased the ability of interferon-γ to produce the mixed lymphocyte reaction to allogenic T cells.
Furthermore, only cotreatment with tumour necrosis factor-α and interferon-γ induced Myb-transformed hematological cells
to express interleukin-6. These results suggest that tumour necrosis factor-α plays a key regulatory role in the development of
dendritic cells from hematological progenitor cells induced by interferon-γ.
1.Introduction
Cytokines are key components of the immune system and
play a crucial role in immune cell developments. An easy
model to study their biological functions is to use hema-
tological progenitor cells. Myb-transformed hematological
cells (MTHCs) were originally derived from fetal mouse liver
and were immortalized by retrovirally vectored Myb gene
transformation [1–3]. Since then, the cell line has been char-
acterized and used as a model of hematological stem cells to
investigatethedevelopmentofhematologicalprogenitorcells
to dendritic cells (DCs) and macrophages [1–3]. Previous
studieshaveshownthatcytokinesplaykeyregulatoryrolesin
the development of MTHCs into either DCs or macrophages
[1–3].Particularly,IL-4andIFN-γ werethecriticalcytokines
that promote the diﬀerentiation of the progenitor cells into
either DC or macrophage lineages. For example, IL-4 plus
TNF-α was shown to promote the MTHCs to develop into
macrophages, while cotreatment of IFN-γ and TNF-α pro-
duced DCs [1, 4–6].
TNF-α was identiﬁed as an endotoxin-induced factor
that caused the necrosis of certain murine tumours in vivo
[7]. As a powerful immune modulator, TNF-α is involved
in systemic inﬂammation and is a member of the cytokines
that stimulate the acute-phase reaction. TNF-α also plays an
important role in the development and maintenance of DCs
[8,9].ItpromotesexpressionofMHCclassIIandcostimula-
tory molecules (CD80 and CD86) [10]. In addition, TNF-α
is essential for host defenses against mycobacteria and other
granulomatous pathogens [11]. Anti-TNF-α treatment of
DCs has been shown to cause apoptosis, indicating the im-
portant role of TNF-α in DC survival [11]. In DC culture,
addition of TNF-α into the culture medium without plasma
could maintain DC viability, while addition of GM-CSF or
IL-4 to the culture medium had no such an eﬀect [12].2 The Scientiﬁc World Journal
DCs are professional antigen-presenting cells (APCs) in-
volved in both innate and adaptive immune responses [4,
13]. DCs also play a key role in the induction of immune
tolerance [14, 15]. Upon stimulation, they secrete cytokines
and activate T cells. The functions of DCs are closely related
to their maturation status and expression of cell markers
for immune modulators such as costimulation factors, CD40
a n dB 7 - 1o nt h ec e l ls u r f a c e[ 16]. Interaction between CD40
and CD40L is considered to be very important in DC mat-
uration and antigen presentation of DCs to T cells [17, 18].
Other studies showed that CD40 was important for the Th1
response, but not for the Th2 response [19]. Understanding
ofthefactorsthatcontributetothediﬀerentiationandmatu-
ration of DCs and their relationship to the function is neces-
sary for possible manipulations of DCs for future treatments
of immune diseases or cancers [20–22].
Although the role of IL-4 and IFN-γ in the development
of hematological progenitor cells into DCs or macrophages
has been well documented, the biological function of TNF-α
tomodulateIL-4andIFN-γ levelstoinducethedevelopment
and diﬀerentiation of DCs from progenitor cells is less well
studied. This prompted us to evaluate the regulatory role of
TNF-α in the induction of dendritic cells from MTHCs with
these two key cytokines. We found that TNF-α promoted the
IFN-γ-induced development of DCs and the generation of
functional DCs from MTHCs through CD40 expression and
antigen processing. Cotreatment of TNF-α and IFN-γ in-
duced MTHCs to express IL-6 mRNA, and TNF-α reduced
the production of IL-12 induced by IFN-γ. These ﬁndings
are valuable for understanding the role of TNF-α in DC cell
development and immunological function.
2.MaterialandMethods
2.1. Cell Lines, Cytokines, and Cell Treatment. The MTHCs
used in this study were prepared from C3H mouse using the
samemethodasdescribedpreviously[23].TheMTHCswere
maintained in modiﬁed IMEM medium (Invitrogen) con-
taining 50unit/mL of GM-CSF and 10% fetal calf serum
(FCS). Mouse GM-CSF, IL-4, and IFN-γ were produced in
insectSf9cellsbyinfectingthecellswithbaculovirusexpress-
ingthecorrespondinggenes.Theconcentrationsweretitered
as described previously [23]. Mouse TNF-α was purchased
from Sigma and was stored at −80◦C in small aliquots until
use.
For cytokine treatment, the cells were cultured in 24-
or 96-well plates and the cytokines were diluted in culture
medium and added directly to the cells. For dose-dependent
CD40 expression experiments, the cells were seeded at a den-
sity of 1 × 106 cells/well in a 24-well plate and the three cor-
responding cytokines were added, respectively. The concen-
trations for IL-4 ranged from 25 to 800units/mL for IFN-γ
they were from 0.5 to 16units/mL and for TNF-α from 50 to
1600units/mL in 2-fold serial dilutions. Twenty-four or 48
hours after treatment the cells were collected for CD40 ex-
pression assays using FACS. For co-treatment with TNF-α +
IFN-γ or TNF-α + IL-4, 200units/mL of TNF-α was used
unless it was speciﬁcally indicated.
2.2. FACS Analysis for CD40 Expression. The cells treated
with diﬀerent cytokines at various doses were harvested by
centrifugation and washed once with 2% fetal calf serum
(FCS)/PBS. The cells were then incubated with 1:10 dilut-
ed monoclonal antibody to mouse CD40 produced from
FGK4.5hybridomafor1hourat37◦C.Thecellswerewashed
twice with 2% FCS/PBS, followed by incubation with the
secondary antibody anti-mouse IgG2 conjugated with FITC
(Santa Cruz Biotechnology) for 1 hour at room temperature.
The cells were washed three times using 2% FCS/PBS, and
ﬁxed in 2% paraﬃn-formaldehyde (PFA)/PBS for ﬂow cy-
tometry (FACS) analysis.
2.3. Antigen Processing. DQ-ovalbumin (DQ-OVA) (Invitro-
gen) is a self-quenched conjugate of ovalbumin that exhibits
green ﬂuorescence when proteolytic degradation in the cells,
which can be measured by ﬂow cytometry. DQ-OVA was
added into 100μL of suspension cells at a concentration of
10μg/mL. The cells were incubated at 37◦Cf o r1h o u r .T h e y
were then washed with 2% FCS/PBS twice, ﬁxed in 2% PFA/
PBS and analyzed using both ﬂow cytometry and confocal
microscopy.
2.4. Mixed Lymphocyte Reaction. The mixed lymphocyte re-
action (MLR) analysis was carried out as previously de-
scribed[23].Brieﬂy,therespondercellswereC57BL/6mouse
spleen cells passed twice through nylon wool column, and
thestimulatorswereMTHCstreatedwithcytokinesandirra-
diated by a 137Cs irradiator (IBL437C, Australia). The cells
were plated in 96-well plates at various ratios of responder
versestimulatorcells,andatleast3repeatsforeachratiowere
set up in the plates. After 4-5 days, the T-cell proliferation
was measured by the uptake of [3H]-thymidine (1pCil/well,
6.7CilmM; ICN, Costa Mesa, Calif, USA), which was added
during the ﬁnal 18 hours of the culture. Cells were harvested
o n t og l a s sﬁ b e rﬁ l t e rp a p e rw i t ha na u t o m a t e d9 6 - w e l lh a r -
vester (Wallac, Turku Finland), and [3H]-thymidine incor-
poration was determined using a liquid scintillation counter.
2.5. Preparation of CD40 Ligand (CD40L) from Insect Cells.
Insect Sf9 cells were cultured in T-75 or T-125 ﬂasks with
IPL-41 medium (Invitrogen) for 3-4 days at 27◦C. When the
cellswere80%conﬂuent,theywereinfectedwithbaculovirus
that expresses mouse CD40L. After culturing for 4-5 days,
the baculovirus-infected cells were harvested and pelleted by
centrifugation. The cell pellets were resuspended in homog-
enization buﬀer and sonicated for 20 seconds on ice. A
volume of 6.6mL homogenizer was transferred into each
10mL ultracentrifuge tubes and underlayered with 2.6mL
40% sucrose solution. The tubes were centrifuged 96000 ×g
for 1 hour at 4◦C. The interfaces were recovered and trans-
ferred into a sterilized 50mL tube and then diluted to 20mL
with PBS. Ten mL of this preparation was transferred into
a Beckman ultracentrifuge tube, and the tubes were centri-
fuged using Ti-50 rotor at 36000rpm for 30 minutes. The su-
pernatant was discarded, and the pellet was resuspended in
10mL PBS. This centrifugation was repeated once more.The Scientiﬁc World Journal 3
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Figure 1: The eﬀect of cytokine treatment on CD40-expression in MTHCs. (a) The FACS results show CD40-positive cells (%) after the 3
cytokine treatments or cotreatments at diﬀerent doses. The doses for IFN-γ (IFN), TNF-α (TNF), and IL-4 treatment alone were as labeled.
For TNF-α co-treatment with IFN-γ and IL-4, TNF-α dose was 200 units/mL and IFN-γ and IL-4 doses were as labeled. The data were the
mean ± SE from 3 separate experiments after 48 hours of treatment. (b) The diagrams show the dot plot analysis of the results from above
treatments. Negative: the antibody isotype control. GM: GM-CSF alone. (c) shows the FACS histogram analysis of ﬂuorescent intensity for
G M+I L - 4+T N F - α (IL-4 +TNF) and GM + IFN-γ +T N F - α (IFN+TNF) groups in (b). Negative: the antibody isotype control.
The pellet was ﬁnally resuspended into 2mL PBS, and the
solution was stored at −70◦C in small aliquots. The prepa-
ration was analysed by Western blotting to detect the CD40L
protein (data not shown) with goat anti-mouse CD40L IgG
(Santa Cruz Biocenology).
2.6.IL-12p40ProteinMeasurement. Thepuriﬁedanti-mouse
IL-12-p40 antibody-coated ELISA kit (ELISA capture, BD
Bioscience,Australia)waspurchasedandusedtomeasureIL-
12p40 protein in the cultural supernatant of MTHCs treated
with diﬀerent cytokines and CD40L, according to the man-
ufacturer’s manual.
2.7. RT-PCR. RT-PCR analysis was carried out as previously
described [24]. Brieﬂy, the treated and untreated cells were
harvested for total RNA extraction using TRIzol reagent
(Invitrogen) according to the manufacturer’s instruction.
Reverse transcription reactions were performed with oligo-
dT primer. The primers for IL-6 RT-PCR were as follows:
forward: 5 -TGCTGGTGACAACCACGGCC; reverse: 5 -
GTACTCCAGAAGACCAGAGG. This resultedin anampliﬁ-
edproductsizeof308nucleotides.Mouseβ-actinwasusedas
internalcontrol(forward:5 -GCTACAGCTTCACCACCACA;
reverse: 5 -TCTCCAGGGAGGAAGAGGAT). The PCR was
performed in 20μLv o l u m ew i t h2 . 5μL 1:10 diluted reverse
transcription product. The PCR program was preheating at
95◦C for 5min; the cycle consisted of 94◦C for 45sec, 56◦C
for 1min, and 72◦C for 2min for a total of 35 cycles.
3. Results
3.1. TNF-α Increased CD40 Expression Induced by IFN-γ,b u t
Not by IL-4. We ﬁrstly examined the eﬀect of individual
cytokines on CD40 expression in MTHCs. CD40 expression
in MTHCs treated with IL-4 or IFN-γ alone was increased
in a dose-dependent manner (Figure 1(a)). TNF-α alone did
not enhance CD40 expression even though it was used in a
dose up to 1600units/mL (Figure 1(a)). To examine whether
TNF-α could increase CD40 expression induced by either IL-
4o rI F N - γ in MTHCs, we cotreated the cells with TNF-α
+IL-4 or TNF-α +I F N - γ. Co-treatment of TNF-α and IL-4
did not further increase CD40 expression of MTHCs, while
co-treatment of TNF-α and IFN-γ signiﬁcantly increased
CD40 expression (Figure 1(a)).
When using dotplot to analyze the co-treatment results,
we found that the CD40 positivity was quite diﬀerent, even
though the ﬁnal percentages of positive cells were similar
(86% and 84.3%, Figure 1(b)). Co-treatment of TNF-α and
IFN-γ resultedin more dead cells(15.4%) than TNF-α +IL-4
treatment (2.8%, Figure 1(b)). When these dead cells were
excluded, the percentage of positive cells was higher than
86%. This is further supported by the comparison of their
mean ﬂuorescence intensity of CD40 expression (68.95 for
the TNF-α +IFN group versus 34.11 for TNF-α +IL-4 group,
Figure 1(c)). Besides, comparing with IL-4 + TNF-α treat-
ment, we found that the co-treatment of IFN-γ and TNF-α
needed to be at least 48 hours to promote CD40 expression,
as 24-hour treatment was not long enough to increase CD40
expression (Figure 2), suggesting that IFN-γ-induced CD40The Scientiﬁc World Journal 5
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Figure 2: TNF-α promotes CD40 expression induced by IFN-γ after 48 hours of treatment. The histogram analysis of CD40 expression in
MTHCs treated with either IFN-γ (2units/mL) or IFN-γ +T N F - α (broken line, IFN+T) is the representative results of FACS analysis from
two separate experiments at 24 and 48 hours after treatment (upper panel). IL-4 and IL-4 + TNF-α (IL-4+T) treatments are shown in the
lower panel. Negative and GM controls are the same as in Figure 1.
expression enhanced by TNF-α was also dependent on the
length of the treatment.
3.2. Cotreatment of IFN-γ and TNF-α Promoted Antigen
Process. We next examined the eﬀect of the treatment of
threecytokinesontheabilityofMTHCstotakeupandproc-
ess antigen DQ-OVA. DQ-OVA has been used as a model
for antigen processing and presentation. According to the
FACS analysis of DQ-OVA ﬂuorescence, MTHCs grown in
GM-CSF medium had a very weak ability to take up and
p r o c e s sD Q - O V A( Figure 3(a)). Treatment with IL-4 alone
did not increase the antigen uptake and processing ability of
MTHCs, whereas the treatment with TNF-α or IFN-γ could
signiﬁcantlyincreasethisabilityoftheMTHCs(Figure 3(a)).
Co-treatment of IL-4 with either TNF-α or IFN-γ could fur-
ther increase the ﬂuorescence intensity (Figure 3(a)), sug-
gesting that IL-4 itself did not have any eﬀect on antigen up-
take and processing. In contrast, co-treatment with IFN-γ
and TNF-α had the greatest ability to increase the ﬂuores-
cence intensity (Figure 3(a)) and show the additive eﬀects on
promoting MTHCs to take up and process the antigen.
To conﬁrm that the antigen was taken up and processed
by MTHCs cotreated with IFN-γ and TNF-α, we examined
the distribution of DQ-OVA in the cells using confocal mi-
croscopy. The images showed that MTHCs treated with6 The Scientiﬁc World Journal
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Figure 3: The ability of cytokine-treated MTHCs to process DQ-OVA antigen in vitro: (a) the mean ﬂuorescent intensity of FACS analysis
shows that MTHCs treated with diﬀerent cytokines have the diﬀerent abilities to process DQ-OVA antigen. Data are expressed as the mean
± SE of three independent experiments. ∗∗∗P<0.001. (b) The representative images of confocal microscopy show the process of DQ-OVA
by MTHCs treated with IFN-γ +T N F - α: (I) MTHCs cultured with GM-CSF only scarcely show any DQ-OVA ﬂuorescent signal on the cell
surface.(II)MTHCstreatedwithIFN-γ +TNF -αhavestrongDQ-OVAsignalsonthecellsurfaces.(III)TheZ-stackimageofcross-scanning
of the positive cells conﬁrms that the processed DQ-OVA antigen (ﬂuorescent signals) was localized on the cell membranes.
IFN-γ plus TNF-α exhibited strong ﬂuorescent signals on
the cell surfaces (Figure 3(b), II), comparing with GM-CSF
(Figure 3(b), I). The cross-cell images demonstrated that
the ﬂuorescent signals were localized on the cell surfaces
(Figure 3(b), III). These data suggest that DQ-OVA antigen
was processed and presented on the cell membrane.
3.3. TNF-α Increased IFN-γ to Produce Strong Mixed Lym-
phocyte Reaction Response to Allogenic T Cells. To examine
whether TNF-α could increase IL-4 or IFN-γ to stimulate T-
cell response in MLR, we used T cells taken from a spleen cell
population of C3H3 mice as the responder and MTHCs
treated with 50units/mL TNF-α together with either IL-4 or
IFN-γ as the stimulator. The stimulator was irradiated before
adding in MLR. The results showed that only the cells treated
with TNF-α together with IFN-γ could stimulate a strong
MLR response to allogenic T cells (Figure 4(a)), suggesting
again that TNF-α could promote IFN-γ but not IL-4 in
stimulating T cells. Furthermore, the cell ratio of responder/
stimulator played a key role in MLR response to allogenic
T cells, with a ratio of 15 producing the maximum reaction
(Figure 4(a)).
A previous study has shown that DCs cultured with
CD40LincreasedcapacitytostimulateallogeneicTcells[25].
To investigate if stimulation of MLR by TNF-α +I F N - γ-
treated MTHCs was associated with CD40 expression or
activation, we also used CD40L in MLR. We observed that
CD40L signiﬁcantly increased the ability of MTHCs treated
withTNF-α and IFN-γ to stimulate MLR response in a dose-
dependent manner (Figure 4(b)).
3.4. Cotreatment of TNF-α and IFN-γ Induced IL-6 mRNA
Expression in MTHCs. To investigate whether co-treatment
of TNF-α and IFN-γ could induce expression of cytokines
that have been shown to be involved in the CD40 expression
and antigen processing, we used RT-PCR analysis to examine
expression of six cytokines including IL-1α and β, IL-3, IL-5,
IL-6, and IL-7 in the MTHCs. The MTHCs were treated withThe Scientiﬁc World Journal 7
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Figure 4: The ability of cytokine-treated MTHCs to stimulate
mixed lymphocyte reaction (MLR). (a) The MLR results with
MTHCs cotreated with 200 unit/mL TNF-α and IL-4 or IFN-γ as
stimulator (S) and enriched T cells from C57BL/6 mouse spleen as
responders (R). Stimulators and responders were set up at diﬀerent
ratios as indicated. (b) The eﬀect of CD40L treatment on MLR:
different doses of CD40L were added to MLR with IFN-γ +T N F - α-
treated MHTCs as stimulators and enriched C57BL/6 spleen T cells
as responders (at the ratio of 3.75). The data were the mean ± SE of
three separate experiments.
the three cytokines individually (IL-4; IFN-γ and TNF-α)o r
withacombinationoftwooutofthethreecytokinesfor24or
48h.ExceptforIL-6,theMTHCsdidnotexpressanymRNAs
of the other ﬁve cytokines examined (data not shown). IL-6
mRNA was detected in the cells treated with a combination
of TNF-α and IFN-γ at 48 hours after treatment but not at
24 hours (Figure 5). The data suggests that TNF-α plus IFN-
γ treatment to MTHCs can induce IL-6 mRNA expression in
these cells, which is similar to CD40 expression.
3.5. Cotreatment with TNF-α and IFN-γ Did Not Promote
IL-12 Production in MTHCs. IL-12 is naturally produced
Table 1: Il-12 p40 protein in the cell culture medium measured by
ELISA (pg/mL).
Treatment 0 1:1000 CD40L 1:500 CD40L
Control <16 <16 43 ±7
IFN <16 34 ±89 7 ±6∗∗
TNF+IFN <16 30 ±11 48 ±6
Notes. ∗∗ P<0.01againstbothcontrolandTNF-IFN.Thevaluesweremean
± SE of 3 experiments. The readings same as blank were regarded as no
protein production and expressed as <16, the limit of the test.
by DCs and facilitate antigen presentation [26]. To further
investigate the possibility of IL-12 involvement in increased
antigen process by the treatment of TNF-α and IFN-γ,w e
examined IL-12 protein in the MTHC culture medium using
ELISA (Table 1). CD40L was added to stimulate the produc-
tion. As shown in Table 1, without presence of CD40L, IL-12
was scarcely detected in the medium. IL-12 was detected in
the presence of CD40L, with a high level detected in the
medium from the IFN-γ-treated MTHC culture (Table 1).
Butthelevelwasreducedwhentreatedwithacombinationof
IFN-γ andTNF-α(Table 1),indicatingthatTNF-αdecreased
IFN-γ-induced IL-12 secretion in MTHCs.
4. Discussion
The process of progenitor cells diﬀerentiating into macro-
phages and DCs is critical for both innate and adaptive im-
munity. CD40 expression is an essential marker for the pro-
genitor cells to develop into mature antigen-presenting cells
[27–29]. CD40 is also a co-stimulatory molecule, and its
ligation with the ligand on T cells can induce the T-cell acti-
v a t i o na n dp r o d u c t i o no fd i ﬀerent proinﬂammatory cytok-
ines. Therefore, in this study, we investigated the eﬀects of
treatments with the three important cytokines on CD40 ex-
pression and antigen process in MTHCs, a model of hema-
tological progenitor cells. Both IL-4 and IFN-γ can induce
CD40 expression in a dose-dependent manner, and TNF-α
can promote IFN-γ-induced CD40 expression in MTHCs. In
addition, only MTHCs cotreated with TNF-α and IFN-γ
showed the profound ability to process the model antigen
DQ-OVA. These data suggest that although both IL-4 and
IFN-γ can play a role in progenitor cell development such as
CD40 expression, IFN-γ has extra ability to cooperate with
TNF-α to promote progenitor cells to diﬀerentiate into more
biologically functional antigen-processing and antigen-pre-
senting cells. These results have more clearly deﬁned the bi-
ofunctional role of TNF-α and IFN-γ in APC development
and maturation.
Indeed, IFN-γ itself has been previously showed to be
a strong CD40 inducer. Nguyen and Benveniste [30]a n d
Nguyen et al. [31] have shown that IFN-γ strongly induces
gene expression of CD40 and that IL-4 inhibits IFN-γ-in-
duced CD40 expression through activation of STAT6 [30,
31]. Using a similar cell line MTHC-D2, Banyer et al. [23]
showed that IFN-γ could induce the progenitor cells to ex-
press several genes important in DC development such as
CD40 expression [23]. Our results, together with the above8 The Scientiﬁc World Journal
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Figure 5: Expression of IL-6 mRNA in cytokine-treated MTHCs: the RT-PCR results show that an IL-6 band is present only in the MTHCs
treated with IFN-γ plus TNF-α at 48 hours but not in other treatments. Ladder: DNA ladders.
studies, suggest that IFN-γ itself has the ability to promote
the development of APCs. In contrast, TNF-α alone or in
combination with CD40 agonist is highly deﬁcient, both
physiologically and functionally in promoting DC matura-
tion [32]. In the current study, we also showed that TNF-α
alone could not increase CD40 expression of the progenitor
cells.However,wedemonstrateherethatIFN-γ withanaddi-
tional help of TNF-α can further promote CD40 expression
and the development of the progenitor cells into functional
APCs that can process an antigen and present a part of the
antigen to the cell surface. A previous study showed that
co-treatment of TNF-α and IFN-γ results in strong syner-
gistic eﬀects on the CD40 expression in activated HK-2 cells
[33].Althoughthecelltypeisdiﬀerentfromours,itsupports
our conclusion.
The data in the current study provide a clear context for
MTHCs to take up and process the model antigen DQ-Oval-
bumin regulated by the cytokines. Antigen process is an im-
portant immunological step for antigen presentation to T
lymphocytes and the subsequent immune response. The
MTHCs had a weak capacity to process DQ-Ovalbumin in
the presence of either GM-CSF or IL-4, but showed strong
capacity in the presence of TNF-α and IFN-γ.T N F - α in-
creased the ability of MTHCs treated with IFN-γ,b u tn o t
with IL-4, to take up and process the antigen. In our study
we showed that IL-4 plus INF-γ treatment was not better
than INF-γ alone in DQ-OVA uptake and processing. This
result is diﬀerent from previous study by Banyer et al. [23]
using MHTC-D2 cells where they showed that co-treatment
with IL-4 and IFN-γ induced the greatest phagocytosis. This
diﬀerence may be caused by diﬀerent cell types used in the
two studies or the diﬀerence in methodologies used in meas-
uring cells to uptake and process antigens as DQ-OVA must
be taken and processed by the cells to exhibit ﬂuorescence
signals.
TNF-α and IFN-γ may simultaneously stimulate respon-
sive genes in many cases [34, 35]. The increase may also be
a result of crosstalk between the TNF-α and IFN-γ signalling
pathways. It has been shown that TNF-α stimulation is able
to induce transcription of IRF-1 and promotes IFN-γ-in-
duced STAT1 activation [36, 37]. The synergistic eﬀect of
TNF-α and IFN-γ has been also shown to be mediated by
NF-κBp a t h w a y[ 38].
The MLRs can produce high levels of type-1 cytokines
including IL-1, IL-6, IFN-γ,a n dT N F - α,b u tl o wo ru n d e -
tectable levels of type-2 cytokines such as IL-4 and IL-10
[39]. In our MLR experiments, the combined treatment with
TNF-α and IFN-γ of the irradiated MTHCs showed a strong
MLR response to allogenic T cells. This is consistent with
a previous study on expression of class II antigens in human
vascular smooth muscle cells (SMCs) [40]. IFN-γ is the only
lymphokine secreted and capable of de novo induction of
MHC class II antigen, HLA-DR expression in SMCs. TNF-α
substantially enhanced IFN-γ-induced expression of HLA-
DQ in MLR [40]. In macrophage, the ability of IFN-γ to
synergize the eﬀects of cytokines such as TNF-α and IL-4 is
particularly important, as macrophages constantly receive
multiplesignalsandneedtointegratethemtogivearesponse
appropriate to the extracellular milieu [38, 41]. Synergistic
activationoftheintercellularmolecule1(ICAM-1)byTNF-α
and IFN-γ is mediated by p65/p50 and p65/c-Rel and inter-
feron-responsive factor Stat1 alpha (p91) that can be acti-
vated by both IFN-γ and IFN-α [42]. Both p50 and p65
proteinscontributetoinductionofcomplementfactorB(Bf)
gene by TNF-α and IFN-γ in macrophages [38].
IL-6, a proinﬂammatory cytokine, can increase adaptive
immune response. It has also been shown to increase the
maturationofDC[43].Weshowthatco-treatmentofTNF-α
and IFN-γ can increase the expression of IL-6 in MTHCs.
IL-6 and TNF-α have been found to control N-glycosylation
patterns of acute-phase plasma proteins [44]. Thus, there is
a possible feed-forward regulation after IL-6 is stimulated
by IFN-γ and TNF-α. Our data are consistent with a recent
study that TNF-α induced mRNA and protein expression
of IL-6 and MCP-1 in both ﬁbroblasts from colorectal
liver metastases and normal liver ﬁbroblasts [45]. TNF-αThe Scientiﬁc World Journal 9
synergized IFN-γ to upregulate expression of Bf gene in
macrophages [38]. Huang et al. [38] identiﬁed that a region
between −556 and −282 bp in the 5  Bf promoter mediated
TNF-α responsiveness and the synergistic eﬀect of TNF-α
and IFN-γ on Bf expression. Site-directed mutagenesis of an
NF-kB-binding element in this region (−433 to −423 bp)
abrogated TNF-α responsiveness and decreased the syner-
gistic eﬀect of TNF-α and IFN-γ on Bf expression [38]. It
has been demonstrated that the interferon-stimulated re-
sponse element and NF-kB mediate synergistic induction of
murine IP-10 gene transcription by IFN-γ and TNF-α [46]
to control IL-6 production [47]. This forward regulation can
promotetherapidmaturationofDCs.Btk-deﬁcientDCsdis-
play a profound impairment of IL-6 and TNF-α production
in response to stimulation by Toll-like receptor-8 (TLR-8)
cognate agonist, ssRNA. Impaired TLR-8-mediated IL-6 and
TNF-α production in antigen-presenting cells from pa-
tients with X-linked agammaglobulinemia was observed
[48]. Here, we have not investigated the mechanisms that
regulate the synergistic eﬀects of TNF-α and IFN-γ on the
upregulated expression of IL-6 in MTHCs, which warrants
further study.
As a T-cell stimulating factor, IL-12 is involved in the
diﬀerentiation of na¨ ıve T cells into Th0 cells which will fur-
therdevelopintoeitherTh1cellsorTh2cells.IL-12canstim-
ulate the growth and function of T cells and plays an impor-
tant role in the activities of natural killer (NK) cells and T
lymphocytes. IL-12 also mediates the enhancement of the
cytotoxic activity of NK cells and CD8+ cytotoxic T lym-
phocytes [26]. It is well known that DCs express and secrete
IL-12 [49]. CD1d-restricted T cells induced myeloid DCs to
secrete IL-12 in the presence of a strong antigenic signal, and
these DCs in turn activated na¨ ıve T cells to secrete Th1
cytokines [49]. T cells that produce IL-12 have a coreceptor,
CD30, which is associated with IL-12 activity [26]. IL-1β
alone signiﬁcantly induced IL-12 production in DCs al-
though TNF-α or IFN-γ induced modest levels of IL-12
production [50]. It appears that CD40 expression is nega-
tively related to the IL-12 production in DCs. Murine bone-
marrow-derivedDCsincubatedwithliveparasitesorparasite
extracts displayed enhanced levels of CD40, but no IL-
10 or IL-12 could be detected in these DCs though small
amounts of IL-6 and TNF-α were secreted by these DCs
[51]. Similarly, we observed here that TNF-α reduced IFN-γ-
induced production of IL-12 in MTHCs. But the mechanism
of how this happens remains unclear though it is speculated
that it could be related to TNF-α increased CD40 expression.
However, further investigation is needed to conﬁrm this.
In summary, we show here that both IL-4 and IFN-γ
can induce CD40 expression in MTHCs. TNF-α signiﬁcantly
increased CD40 expression induced by IFN-γ,b u tn o tb yI L -
4i nM T H C s .T N F - α synergized IFN-γ to take up and proc-
ess antigen on cell surface and promoted IFN-γ to produce
strong MLR response to allogenic T cells. TNF-α enhanced
IFN-γ-induced expression of IL-6 mRNA and reduced the
secretion of IL-12 induced by IFN-γ. The results indicate
the key regulatory role of TNF-α in the development and
diﬀerentiation of functional DCs from the MTHCs, which
facilitateourunderstandingonDCdevelopmentfromhema-
tological stem or progenitor cells.
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